TScan Therapeutics annual net debt
2020
2021
2022
2023
2024
2025
TScan Therapeutics Net Debt Growth & History (TCRX)
TScan Therapeutics's net debt was −$58.3M for fiscal 2025.
View full TScan Therapeutics company overviewTScan Therapeutics annual net debt history
| Fiscal year | Period ended | Net debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$58.3M | $23.0M | — |
| 2024 | 2024-12-31 | −$81.3M | −$40.4M | — |
| 2023 | 2023-12-31 | −$40.9M | −$6.9M | — |
| 2022 | 2022-12-31 | −$34.0M | $121.3M | — |
| 2021 | 2021-12-31 | −$155.4M | −$128.0M | — |
| 2020 | 2020-12-31 | −$27.4M | — | — |
TScan Therapeutics quarterly net debt
Q4.20
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Net debt | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$9.3M | $63.4M | — |
| Q1 2026 | 2026-03-31 | −$35.5M | $21.6M | — |
| Q4 2025 | 2025-12-31 | −$58.3M | $23.0M | — |
| Q3 2025 | 2025-09-30 | −$73.9M | −$31.1M | — |
| Q2 2025 | 2025-06-30 | −$72.7M | $78.4M | — |
| Q1 2025 | 2025-03-31 | −$57.1M | −$8.3M | — |
| Q4 2024 | 2024-12-31 | −$81.3M | −$40.4M | — |
| Q3 2024 | 2024-09-30 | −$42.8M | $25.4M | — |
| Q2 2024 | 2024-06-30 | −$151.1M | −$30.0M | — |
| Q1 2024 | 2024-03-31 | −$48.8M | −$38.5M | — |
| Q4 2023 | 2023-12-31 | −$40.9M | −$6.9M | — |
| Q3 2023 | 2023-09-30 | −$68.2M | $35.2M | — |
| Q2 2023 | 2023-06-30 | −$121.1M | −$742,000 | — |
| Q1 2023 | 2023-03-31 | −$10.3M | $124.9M | — |
| Q4 2022 | 2022-12-31 | −$34.0M | $121.3M | — |
| Q3 2022 | 2022-09-30 | −$103.4M | $72.5M | — |
| Q2 2022 | 2022-06-30 | −$120.4M | −$20.9M | — |
| Q1 2022 | 2022-03-31 | −$135.2M | — | — |
| Q4 2021 | 2021-12-31 | −$155.4M | −$128.0M | — |
| Q3 2021 | 2021-09-30 | −$175.9M | — | — |
| Q2 2021 | 2021-06-30 | −$99.4M | — | — |
| Q4 2020 | 2020-12-31 | −$27.4M | — | — |
TScan Therapeutics net debt trends
Over the last five fiscal years, TScan Therapeutics's net debt decreased from −$27.4M to −$58.3M, a change of −$30.9M. The latest reported quarter, Q2 2026, shows −$9.3M.
About the metric
What net debt means
Net debt compares a company’s interest-bearing debt with its cash and cash equivalents. Positive net debt means debt exceeds cash, while a negative value indicates the company has more cash than debt on this measure.
Calculation and source
How net debt is calculated
TickerStat calculates net debt as total interest-bearing debt minus cash and cash equivalents at the same reporting-period end. Short-term investments are not subtracted because they are not included in the standardized cash series. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review TScan Therapeutics source filings ↗